Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non-responders: Subgroup analysis of UNCOVER-3 trial.

Autor: Rosmarin D; Tufts Medical Center Boston Massachusetts USA., Smith S; California Dermatology and Clinical Research Institute Encinitas California USA., Shrom D; Eli Lilly and Company Indianapolis Indiana USA., Burge R; Eli Lilly and Company Indianapolis Indiana USA.; Division of Pharmaceutical Sciences University of Cincinnati Cincinnati Ohio USA., See K; Eli Lilly and Company Indianapolis Indiana USA., McKean-Matthews M; Syneos Health Morrisville North Carolina USA., Ridenour T; Eli Lilly and Company Indianapolis Indiana USA., Lin CY; Eli Lilly and Company Indianapolis Indiana USA., Gorelick J; California Skin Institute San Jose California USA.

Publikováno v: Skin health and disease [Skin Health Dis] 2021 May 11; Vol. 1 (3), pp. e43. Date of Electronic Publication: 2021 May 11 (Print Publication: 2021).

Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.

Autor: Augustin, Matthias¹ (AUTHOR) m.augustin@uke.de, Gottlieb, Alice B.² (AUTHOR), Lebwohl, Mark² (AUTHOR), Pinter, Andreas³ (AUTHOR), Warren, Richard B.^4,5 (AUTHOR), Puig, Luis⁶ (AUTHOR), Warham, Rhys^7,8 (AUTHOR), Lambert, Jérémy⁹ (AUTHOR), Wiegratz, Susanne¹⁰ (AUTHOR), Szilagyi, Balint¹⁰ (AUTHOR), Blauvelt, Andrew¹¹ (AUTHOR)

Publikováno v: Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2841-2857. 17p.

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials ( UNCOVER-1, UNCOVER-2 and UNCOVER-3).

Autor: Menter, A., Warren, R.B., Langley, R.G., Merola, J.F., Kerr, L.N., Dennehy, E.B., Shrom, D., Amato, D., Okubo, Y., Reich, K.

Publikováno v: Journal of the European Academy of Dermatology & Venereology; Oct2017, Vol. 31 Issue 10, p1686-1692, 7p

713 The association between disease severity at time of retreatment and probability of recapture in psoriasis patients receiving ixekizumab

Autor: Leonardi, C., Mroweitz, U., See, K., Shrom, D., McKean-Matthews, M., Gallo, G., Nickoloff, B.J., Wu, J.

Publikováno v: In Journal of Investigative Dermatology May 2019 139(5) Supplement:S122-S122

Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study.

Autor: Puig L; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Zhu B; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Burge R; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Shrom D; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Dong Y; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Shen W; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Mallbris L; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany., Reich K; Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain.; Drs. Zhu, Burge, Shrom, Dong, Shen, and Mallbris are with Eli Lilly and Company in Indianapolis, Indiana.; Dr. Burge is also with the University of Cincinnati in Cincinnati, Ohio.; Dr. Reich is with the Institute for Health Services Research in Dermatology and Nursing at the University Medical Center Hamburg-Eppendorf and Skinflammation® Center in Hamburg, Germany.

Publikováno v: The Journal of clinical and aesthetic dermatology [J Clin Aesthet Dermatol] 2020 Oct; Vol. 13 (10), pp. 18-22. Date of Electronic Publication: 2020 Oct 01.